BACKGROUND: We sought to measure trends in Streptococcus pneumoniae carriage and antibiotic resistance in young children in Massachusetts communities after widespread adoption of heptavalent 7-valent pneumococcal conjugate vaccine (PCV7) and before the introduction of the 13-valent PCV (PCV13). METHODS: We conducted a cross-sectional study including collection of questionnaire data and nasopharyngeal specimens among children aged <7 years in primary care practices from 8 Massachusetts communities during the winter season of 2008-2009 and compared with similar studies performed in 2001, 2003-2004, and 2006-2007. Antimicrobial susceptibility testing and serotyping were performed on pneumococcal isolates, and risk factors for colonization in recent seasons (2006-2007 and 2008-2009) were evaluated. RESULTS: We collected nasopharyngeal specimens from 1011 children, 290 (29%) of whom were colonized with pneumococcus. Non-PCV7 serotypes accounted for 98% of pneumococcal isolates, most commonly 19A (14%), 6C (11%), and 15B/C (11%). In 2008-2009, newly targeted PCV13 serotypes accounted for 20% of carriage isolates and 41% of penicillin-nonsusceptible S. pneumoniae. In multivariate models, younger age, child care, young siblings, and upper respiratory illness remained predictors of pneumococcal carriage, despite near-complete serotype replacement. Only young age and child care were significantly associated with penicillin-nonsusceptible S. pneumoniae carriage. CONCLUSIONS: Serotype replacement post-PCV7 is essentially complete and has been sustained in young children, with the relatively virulent 19A being the most common serotype. Predictors of carriage remained similar despite serotype replacement. PCV13 may reduce 19A and decrease antibiotic-resistant strains, but monitoring for new serotype replacement is warranted.
BACKGROUND: We sought to measure trends in Streptococcus pneumoniae carriage and antibiotic resistance in young children in Massachusetts communities after widespread adoption of heptavalent 7-valent pneumococcal conjugate vaccine (PCV7) and before the introduction of the 13-valent PCV (PCV13). METHODS: We conducted a cross-sectional study including collection of questionnaire data and nasopharyngeal specimens among children aged <7 years in primary care practices from 8 Massachusetts communities during the winter season of 2008-2009 and compared with similar studies performed in 2001, 2003-2004, and 2006-2007. Antimicrobial susceptibility testing and serotyping were performed on pneumococcal isolates, and risk factors for colonization in recent seasons (2006-2007 and 2008-2009) were evaluated. RESULTS: We collected nasopharyngeal specimens from 1011 children, 290 (29%) of whom were colonized with pneumococcus. Non-PCV7 serotypes accounted for 98% of pneumococcal isolates, most commonly 19A (14%), 6C (11%), and 15B/C (11%). In 2008-2009, newly targeted PCV13 serotypes accounted for 20% of carriage isolates and 41% of penicillin-nonsusceptible S. pneumoniae. In multivariate models, younger age, child care, young siblings, and upper respiratory illness remained predictors of pneumococcal carriage, despite near-complete serotype replacement. Only young age and child care were significantly associated with penicillin-nonsusceptible S. pneumoniae carriage. CONCLUSIONS: Serotype replacement post-PCV7 is essentially complete and has been sustained in young children, with the relatively virulent 19A being the most common serotype. Predictors of carriage remained similar despite serotype replacement. PCV13 may reduce 19A and decrease antibiotic-resistant strains, but monitoring for new serotype replacement is warranted.
Authors: William P Hanage; Tarja H Kaijalainen; Ritva K Syrjänen; Kari Auranen; Maija Leinonen; P Helena Mäkelä; Brian G Spratt Journal: Infect Immun Date: 2005-01 Impact factor: 3.441
Authors: William P Hanage; Susan S Huang; Marc Lipsitch; Cynthia J Bishop; Daniel Godoy; Stephen I Pelton; Richard Goldstein; Heather Huot; Jonathan A Finkelstein Journal: J Infect Dis Date: 2006-12-27 Impact factor: 5.226
Authors: Susan S Huang; Richard Platt; Sheryl L Rifas-Shiman; Stephen I Pelton; Donald Goldmann; Jonathan A Finkelstein Journal: Pediatrics Date: 2005-09 Impact factor: 7.124
Authors: Rekha Pai; Matthew R Moore; Tamara Pilishvili; Robert E Gertz; Cynthia G Whitney; Bernard Beall Journal: J Infect Dis Date: 2005-11-01 Impact factor: 5.226
Authors: Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson Journal: JAMA Date: 2007-04-25 Impact factor: 56.272
Authors: Sheldon L Kaplan; Edward O Mason; Ellen R Wald; Gordon E Schutze; John S Bradley; Tina Q Tan; Jill A Hoffman; Laurence B Givner; Ram Yogev; William J Barson Journal: Pediatrics Date: 2004-03 Impact factor: 7.124
Authors: Carlos G Grijalva; J Pekka Nuorti; Patrick G Arbogast; Stacey W Martin; Kathryn M Edwards; Marie R Griffin Journal: Lancet Date: 2007-04-07 Impact factor: 79.321
Authors: Grace M Lee; Ken Kleinman; Stephen I Pelton; William Hanage; Susan S Huang; Matthew Lakoma; Maya Dutta-Linn; Nicholas J Croucher; Abbie Stevenson; Jonathan A Finkelstein Journal: J Pediatric Infect Dis Soc Date: 2013-10-03 Impact factor: 3.164
Authors: Judith M Martin; Alejandro Hoberman; Jack L Paradise; Karen A Barbadora; Nader Shaikh; Sonika Bhatnagar; Timothy Shope; Stan L Block; Mary Ann Haralam; Marcia Kurs-Lasky; D Kathleen Colborn; Michael Green Journal: Pediatr Infect Dis J Date: 2014-11 Impact factor: 2.129
Authors: Grace M Lee; Ken Kleinman; Stephen Pelton; Marc Lipsitch; Susan S Huang; Matt Lakoma; Maya Dutta-Linn; Melisa Rett; William P Hanage; Jonathan A Finkelstein Journal: Pediatrics Date: 2017-10-04 Impact factor: 7.124